| __timestamp | Dyne Therapeutics, Inc. | Jazz Pharmaceuticals plc |
|---|---|---|
| Wednesday, January 1, 2014 | 1145000000 | 117418000 |
| Thursday, January 1, 2015 | 2028000000 | 102526000 |
| Friday, January 1, 2016 | 2281000000 | 105386000 |
| Sunday, January 1, 2017 | 2932000000 | 110188000 |
| Monday, January 1, 2018 | 24000 | 121544000 |
| Tuesday, January 1, 2019 | 271000 | 127930000 |
| Wednesday, January 1, 2020 | 700000 | 148917000 |
| Friday, January 1, 2021 | 1088000 | 440760000 |
| Saturday, January 1, 2022 | 3345000 | 540517000 |
| Sunday, January 1, 2023 | 2461000 | 435577000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical landscape, understanding cost dynamics is crucial. Jazz Pharmaceuticals plc and Dyne Therapeutics, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2017, Dyne Therapeutics saw a staggering increase in its cost of revenue, peaking at nearly 2.9 billion in 2017. However, post-2017, the company experienced a dramatic decline, with costs plummeting to just 24,000 in 2018. This volatility highlights the challenges faced by emerging biotech firms.
Conversely, Jazz Pharmaceuticals maintained a more stable trajectory. Starting at approximately 117 million in 2014, their cost of revenue grew steadily, reaching a high of 540 million in 2022. This consistent growth underscores Jazz's strategic management and market positioning. As we look to the future, these trends offer valuable insights into the operational efficiencies and market strategies of these two industry players.
Cost Insights: Breaking Down AbbVie Inc. and Jazz Pharmaceuticals plc's Expenses
AstraZeneca PLC vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Novartis AG vs Dyne Therapeutics, Inc.
Cost of Revenue: Key Insights for Sanofi and Dyne Therapeutics, Inc.
United Therapeutics Corporation vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Jazz Pharmaceuticals plc and Halozyme Therapeutics, Inc.'s Expenses
Cost of Revenue Trends: Jazz Pharmaceuticals plc vs Iovance Biotherapeutics, Inc.
Cost of Revenue Comparison: Jazz Pharmaceuticals plc vs BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down MorphoSys AG and Dyne Therapeutics, Inc.'s Expenses
Cost Insights: Breaking Down Mesoblast Limited and Dyne Therapeutics, Inc.'s Expenses
Cost Insights: Breaking Down Travere Therapeutics, Inc. and Dyne Therapeutics, Inc.'s Expenses
Cost of Revenue Comparison: Dyne Therapeutics, Inc. vs Viridian Therapeutics, Inc.